The Daily Scan

July 16, 2018

Last Updated: 9:00 AM EST

Regulation

  • The New York State Department of Health delivered a regulated Marijuana Impact Assessment for Governor Cuomo's review. The report concluded: "The positive effects of a regulated marijuana market in NYS outweigh the potential negative impacts. Areas that may be a cause for concern can be mitigated with regulation and proper use of public education that is tailored to address key populations. Incorporating proper metrics and indicators will ensure rigorous and ongoing evaluation." Notably, the report estimated that in the first year of legalization alone, potential tax revenue could be as much as $677.7 million. (Health.NY.gov)

 

  • On Friday, the U.S. Food and Drug Administration approved TPOXX (tecovirimat), the first drug with an indication for treatment of smallpox. Though the World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, eradicated in 1980, there have been longstanding concerns that smallpox could be used as a bioweapon. “To address the risk of bioterrorism, Congress has taken steps to enable the development and approval of countermeasures to thwart pathogens that could be employed as weapons. Today’s approval provides an important milestone in these efforts. This new treatment affords us an additional option should smallpox ever be used as a bioweapon,” said FDA Commissioner Scott Gottlieb, M.D. "This is the first product to be awarded a Material Threat Medical Countermeasure priority review voucher. Today’s action reflects the FDA’s commitment to ensuring that the U.S. is prepared for any public health emergency with timely, safe and effective medical products.” (FDA.gov)

Litigation

  • The U.S. Department of Health and Human Services released a statement on Friday on Ms. L et al. v. ICE: "In today’s filing in the U.S. District Court for the Southern District of California, it is mentioned that HHS has identified 2,551 minors 5 to 17 years of age in the department’s custody who could potentially have been separated from a parent at the time of entry into the United States and therefore could potentially be eligible for reunification with a parent in DHS custody. This number represents the total possible cohort of minors who could potentially be subject to the court order, and, based on past experience, includes a significant number of minors who cannot or should not be reunified with the adults in question. The number is not the number of minors who will eventually qualify for reunification and be reunified. It is not, nor should it be, our objective to reunify all 2,551 minors with the adult whom they arrived here with, because some of those adults are not their parents or pose a clear danger to the children." (HHS.gov)

Private Sector

  • Novartis, a Swiss pharmaceutical company, released an updated statement on its consulting contract with Essential Consultants, the company owned by Michael Cohen, President Trump's former personal attorney. The comments came in response to inquiries and an investigative report from several U.S. Senators. Novartis stated: "Following the revelations concerning Novartis’ former consulting contract with Michael Cohen and Essential Consultants, we received inquiries from several U.S. Senators. We cooperated with those inquiries and today the Senators issued a report detailing their findings. We disagree with the report’s conclusion that we issued a misleading public statement regarding the extent of our engagement with Mr. Cohen...As we have already acknowledged, Novartis made a mistake in entering into the contract with Michael Cohen. And in hindsight – and certainly knowing everything we know now – we should have tried to terminate the contract with Mr. Cohen regardless of our views at the time of its legal enforceability." (Novartis.com)

 

 

 

Please reload

Our Recent Posts

The Weekly Scan

April 26, 2019

The Weekly Scan

April 12, 2019

The Weekly Scan

April 5, 2019

1/1
Please reload

Tags

Please reload

 

©2018 by FHAS Inc.

1 PPG Place, 31st Floor,

Pittsburgh, PA 15222